Arbutus Biopharma Corporation
ABUS
$5.16
-$0.02-0.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.14M | 169.70M | -3.76M | -7.74M | 2.52M |
| Total Depreciation and Amortization | 11.00K | 11.00K | 11.00K | 11.00K | 11.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.35M | 1.05M | -2.73M | 764.00K | -43.00K |
| Change in Net Operating Assets | -2.24M | -178.87M | 1.80M | 1.15M | -18.24M |
| Cash from Operations | -6.02M | -8.11M | -4.68M | -5.82M | -15.75M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 355.00K | 0.00 | 9.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.66M | 2.20M | -1.72M | -10.02M | 15.60M |
| Cash from Investing | -1.66M | 2.20M | -1.36M | -10.02M | 15.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.15M | 11.62M | 1.64M | 844.00K | 453.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.15M | 11.62M | 1.64M | 844.00K | 453.00K |
| Foreign Exchange rate Adjustments | -4.00K | -10.00K | 1.00K | -12.00K | 21.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.54M | 5.70M | -4.40M | -15.00M | 336.00K |